PCI starts work on another expansion

PCI is adding potent handling capabilities at its site in the U.K. (PCI Pharma Services)

Having only just completed an expansion of its clinical supply facility in Illinois, PCI Pharma Services will now expand its solid dose facility in Wales in the U.K. 

Philadelphia-based PCI says it is doubling the large-scale granulation and fluid bed drying capacity at the Wales facility. It also is adding space for new potent handling capabilities as well as areas for additional analytical and small-scale processing that will permit it to do early-stage, non-GMP processing and formulation. 

RELATED: PCI debuts expansion of its Rockford, Illinois, facility

Survey

Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

It expects the expansion to be complete in 2021. It did not disclose its investment. 

The work in the U.K. follows completion of a 30,000-square-foot expansion of PCI's facility in Rockford, Illinois, where it added primary and secondary packaging as well as labeling for clinical supplies. It also included a temperature-controlled suite

Earlier in the year, the company said it would add a 75,000-square-foot clinical supply facility near Dublin that can handle both primary and secondary packaging, storage, logistics and distribution.

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.